TESARO Inc

Type: Company
Name: TESARO Inc
Nationality: United States
Web Address: http://tesarobio.com/
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Business Digest for Sept. 26, 2014

Body Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW. Framingham to host TRADEWorks! TRADEWorks! Table Top Trade Show & Networking Series, presented by the MetroWest Chamber of Commerce and TD Bank, takes place Oct. 3 from 7:30 ... [Published MetroWest Daily News - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Convertible notes sale nets $170mm for Tesaro

Tesaro Inc. (cancer therapeutics) netted $170mm through the public sale of $175mm of its 3% senior notes due 2021. The notes convert to common at a rate of 28.4627 shares per $1k principal amount, or $35.13. (Tesaro's stock was averaging $29.09.)...Related ... [Published BioPortfolio - Sep 26 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

TRACON Pharmaceuticals Expands Management Team and Board of Directors

Paul Walker is a partner in NEA's Menlo Park Office. He is a board observer of Sunesis and Interleukin Genetics, a former board member of TESARO (NASDAQ: TRSO), and manages a number of NEA's other late-stage and public investments.... ... [Published Town Hall - Sep 24 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Business Digest for Sept. 24, 2014

Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW. State's jobless rates drop in 13 areas in August The Executive Office of Labor and Workforce Development this week reported that the seasonally unadjusted unemployment rates for ... [Published Wicked Local Wayland - Sep 24 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

TESARO Prices $175 Million Notes Offering

TESARO, Inc. (Nasdaq:TSRO) announced today the pricing of $175 million aggregate principal amount of its 3.00% convertible senior notes due 2021 in an underwritten public offering. The size of the offering was increased from the previously announced aggregate ... [Published Citybizlist - Sep 24 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Airstrikes against terrorist groups send markets tumbling

U.S. airstrikes against terrorist groups sent the markets tumbling to a sharply lower close with the Dow plunging 116 points to 17,055. Nasdaq fell 19 points to 4,508.On the upsideBargain hunters lifted shares of Sino-Global Shipping America ( Nasdaq: ... [Published Market Pulse Navigator - Sep 23 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

305B2 - TESARO, Inc. (0001491576) (Filer)

Document Format FilesSeq Description Document Type Size 1 305B2 a14-21259_3305b2.htm 305B2 71564 2 GRAPHIC g212593bei001.gif GRAPHIC 40341 3 GRAPHIC g212593bei002.gif GRAPHIC 45453 Complete submission text file 0001104659-14-067636.txt 191135 ... [Published SEC - Sep 23 2014]
Entities: TESARO Inc
First reported Sep 16 2014 - Updated Sep 16 2014 - 2 reports

Business Digest for Sept. 16, 2014

Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW.Waltham's Tesaro submits rolapitant applicationTesaro Inc., a Waltham-based oncology-focused biopharmaceutical company, this week announced that it has submitted the new drug application ... [Published Wicked Local Ashland - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More

It’s back to work, back to school, and back to the grind in biotech. One local company inched towards a potential FDA approval, yet its stock is down more than 10 percent. Another biotech came under fire for a big price hike on an old drug. And a new ... [Published Xconomy - Sep 15 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 2 reports

Opko Health: Licensee Tesaro Submits NDA for Rolapitant to Prevent CINV

Opko Health reported that its licensee, Tesaro has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the ... [Published Individual.com - Sep 11 2014]
First reported Sep 09 2014 - Updated Sep 10 2014 - 4 reports

TESARO submits NDA for chemotherapy-induced nausea and vomiting drug to FDA

OPKO Health, Inc., a biopharmaceutical and diagnostics company, has announced that its licensee, TESARO, Inc. a biopharmaceutical company, has submitted a new drug application, or NDA, to the FDA for approval of oral rolapitant, an investigational neurokinin-1 ... [Published Individual.com - Sep 10 2014]
First reported Sep 08 2014 - Updated Sep 09 2014 - 11 reports

Tesaro seeks US FDA approval for rolapitant for prevention of CINV

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, announced that its licensee, Tesaro, Inc. has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational ... [Published PharmaBiz - Sep 09 2014]

Quotes

Eric Wachter, PhD and Chief Technology Officer of Provectus, said, "We are very pleased to share the patient-level PFS data at ESMO that defined our design parameters for the upcoming phase 3 trial. These study results demonstrate the potential of an intralesional approach to delay progression while alleviating symptoms of locally advanced melanoma."
Hemispherx Biopharma Inc. (NYSE MKT:HEB) , announced today a peer-reviewed publication entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1) by Low Dose Natural Human IFN-α Administered to the Buccal Mucosa" in the current issue of Antiviral Research 2014
Original Article: NEXT ARTICLE More From BioPortfolio on "AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer"
"We are pleased by the very professional work of the Tesaro team in completing the studies required to file the NDA. Opko's other internal projects are progressing as planned and we are anxious to introduce these important new products to the market as rapidly as possible" said Phillip Frost, M D , Chairman and Chief Executive Officer of Opko

More Content

All (89) | News (57) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (0) | Press Releases (17)
sort by: Date | Relevance
Medidata Appoints Mike Capone COO; PV-10 Data a... [Published BioMedReports - 14 hours ago]
TESARO Announces Closing of $201.25 Million Pub... [Published GlobeNewswire: Acquisitions News - 18 hours ago]
Business Digest for Sept. 26, 2014 [Published MetroWest Daily News - Sep 26 2014]
Convertible notes sale nets $170mm for Tesaro [Published BioPortfolio - Sep 26 2014]
TRACON Pharmaceuticals Expands Management Team ... [Published Town Hall - Sep 24 2014]
Business Digest for Sept. 24, 2014 [Published Wicked Local Wayland - Sep 24 2014]
TESARO Prices $175 Million Notes Offering [Published Citybizlist - Sep 24 2014]
TESARO Announces Pricing of $175 Million of 3.0... [Published GlobeNewswire: Acquisitions News - Sep 24 2014]
Airstrikes against terrorist groups send market... [Published Market Pulse Navigator - Sep 23 2014]
Tracon Pharmaceuticals racks up $27 mln Series B [Published PE Hub Blog - Sep 23 2014]
305B2 - TESARO, Inc. (0001491576) (Filer) [Published SEC - Sep 23 2014]
Neuralstem Announces ALS Long-Term Follow-Up Ph... [Published BioMedReports - Sep 23 2014]
TESARO Announces Offering of $165 Million of Co... [Published GlobeNewswire: Advertising News - Sep 22 2014]
TESARO Announces Offering of $165 Million of Co... [Published Fat Pitch Financials - Sep 22 2014]
TRACON Pharmaceuticals, Inc. : TRACON Pharmaceu... [Published Investegate - Sep 22 2014]
TRACON Pharmaceuticals Completes and#36;27 Mill... [Published SPi World News - Sep 22 2014]
TRACON Pharmaceuticals Completes $27 Million Fi... [Published Franklin Credit Management Corporation - Sep 22 2014]
Business Digest for Sept. 16, 2014 [Published Wicked Local Ashland - Sep 16 2014]
Business Digest for Sept. 16, 2014 [Published MetroWest Daily News - Sep 16 2014]
East Coast Biotech Roundup: Maraganore, Flex, N... [Published Xconomy - Sep 15 2014]
AstraZeneca is developing new PARP inhibitor fo... [Published BioPortfolio - Sep 11 2014]
Opko Health: Licensee Tesaro Submits NDA for Ro... [Published Individual.com - Sep 11 2014]
Tesaro Turns in New Drug Application for Rolapi... [Published Individual.com - Sep 11 2014]
TESARO submits NDA for chemotherapy-induced nau... [Published Individual.com - Sep 10 2014]
Nausea and Vomiting Treatment Rolapitant Submit... [Published PT Community - Sep 09 2014]
TESARO Announces Submission of Rolapitant New D... [Published Pappas Ventures - Sep 09 2014]
TESARO Seeks FDA Approval for NK-1 Receptor Rol... [Published Zacks.com - Sep 09 2014]
Rolapitant Submitted for Approval for Preventio... [Published Chemotherapy Advisor - Sep 09 2014]
Tesaro seeks US FDA approval for rolapitant for... [Published PharmaBiz - Sep 09 2014]
EBS Gets Funded, HPTX Pulls Plug On Diabetes Dr... [Published RTTNews.com - Sep 09 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Tracon Pharmaceuticals racks up $27 mln Series B [Published PE Hub Blog - Sep 23 2014]
Tracon Pharmaceuticals has closed $27 million in Series B funding. The investors included New Enterprise Associates, BioMed Ventures, JAFCO Co., Nextech Invest, Brookline Investments, Arcus Ventures and BHP. MTS Health Partners and Wells Fargo ...
OPKO Licensee TESARO Submits New Drug Applicati... [Published Business Wire Health News - Sep 08 2014]
MIAMI--(BUSINESS WIRE)--Tesaro New Drug Application ...
Paradigm collaborates with TESARO on molecular ... [Published PBR - News - Aug 21 2014]
Paradigm today announced a collaboration with TESARO. ...
Paradigm Announces Molecular Profiling Collabor... [Published PR Newswire: Health - Aug 20 2014]
ANN ARBOR, Mich. and PHOENIX, Aug. 20, 2014 /PRNewswire-USNewswire/ -- Paradigm, a non-profit corporation established to bring cutting-edge next-generation sequencing and proteomic diagnostics and biomarker driven clinical trials to cancer patients, ...
Boston CEO Conference to Feature CEOs of Aegeri... [Published Business Wire Health News - May 20 2014]
BOSTON--(BUSINESS WIRE)--More than 200 leading CEOs from the biotechnology community will gather at the 2014 Boston CEO Conference June 4th and 5th at the Four Seasons Hotel in Boston. Past award winners Henri Termeer, Josh Boger, Deborah Dunsire and ...
1 2 3

Press Releases

sort by: Date | Relevance
TESARO Announces Closing of $201.25 Million Pub... [Published GlobeNewswire: Acquisitions News - 18 hours ago]
TESARO Announces Pricing of $175 Million of 3.0... [Published GlobeNewswire: Acquisitions News - Sep 24 2014]
TESARO Announces Offering of $165 Million of Co... [Published GlobeNewswire: Advertising News - Sep 22 2014]
TESARO Announces Submission of Rolapitant New D... [Published GlobeNewswire: Advertising News - Sep 08 2014]
TESARO Announces Participation at Several Upcom... [Published GlobeNewswire: Acquisitions News - Aug 21 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.